By: Roxanne Nelson, RN, BSN From: medscape.com In concluding their review of hormone replacement therapy (HRT) and the associated risk of breast cancer, the EU Pharmacovigilance Risk Assessment Committee (PRAC) has recommended updating current safety information. PRAC is the European Medicine Agency’s (EMA) committee that is responsible for assessing the safety of human medications, and it has based this latest …